Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that HER2-positive status confers therapeutic sensitivity to Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab in patients with Invasive Breast Carcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab, paclitaxel, and carboplatin (TRAIN-2) for reimbursement as a treatment option for the neoadjuvant treatment of HER2-positive, locally advanced, inflammastory, or early stage breast cancer at high risk of recurrence in adult patients.
This statement is based on a regulatory approval from the Health Service Executive:
Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.